Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
This suggestion was confirmed by immunohistochemical studies
2024-04-01
This suggestion was confirmed by immunohistochemical studies in which the immunoreactivity of the enzyme was actually higher at the earlier rather than at the advanced stages of the disease. Importantly, a later study showed that the biochemical signature of 12/15LO enzymatic activation (i.e., 12-HE
-
br GMF Remodels Actin Networks at the Leading Edge How
2024-04-01
GMF Remodels Actin Networks at the Leading Edge How are the conserved activities of GMF used in vivo to regulate branched Quinupristin-Dalfopristin Complex mesylate networks (e.g., at sites of endocytosis and at the leading edge) (Figure 2A,B)? In animal cells, the regulatory effects of GMF on a
-
We have previously reported alterations of the thymus
2024-04-01
We have previously reported alterations of the thymus in AChR-MG patients, especially in their germinal center L-NMMA citrate (defined as CD19+CD38+ cells by flow cytometric analysis). First, we found that, in MG thymi, this subset failed to show the normal down-regulation of Bcl-2, suggesting that
-
In the U S surveillance of
2024-04-01
In the U.S., surveillance of ACEs has garnered traction at the state level through administration of the ACE Optional Module in CDC’s Behavioral Risk Factor Surveillance System (BRFSS) (Centers for Disease Control & Prevention, 2003). Since 2009, select states have implemented the ACEs optional modu
-
Vortioxetine is a multimodal antidepressant that acts as
2024-04-01
Vortioxetine is a multimodal antidepressant that acts as an inhibitor at the serotonin (5-HT) transporter (SERT), an agonist at 5-HT1A receptors, a partial agonist at 5-HT1B receptors, and an antagonist at 5-HT1D, 5-HT3 and 5-HT7 receptors (Bang-Andersen et al., 2011, Sanchez et al., 2015). Based on
-
br Conclusions Triptans are HT B D F
2024-04-01
Conclusions Triptans are 5-HT1B/1D/(1F) receptors agonists and are considered as the gold standard for acute migraine treatment that have been proven effective. Unfortunately, they are contraindicated in patients with cardiovascular diseases due to their vasoconstrictor (side) effects (MaassenVan
-
Vortioxetine is a multimodal antidepressant that acts as
2024-04-01
Vortioxetine is a multimodal antidepressant that acts as an inhibitor at the serotonin (5-HT) transporter (SERT), an agonist at 5-HT1A receptors, a partial agonist at 5-HT1B receptors, and an antagonist at 5-HT1D, 5-HT3 and 5-HT7 receptors (Bang-Andersen et al., 2011, Sanchez et al., 2015). Based on
-
In conclusion AXL overexpression preexisted in
2024-04-01
In conclusion, AXL overexpression preexisted in a subgroup of treatment-naive lung adenocarcinoma specimens harboring an activating EGFR mutation or in those with wild-type EGFR. Anti-AXL therapeutics delivered up front in combination with the EGFR inhibitor might overcome intrinsic or acquired resi
-
In addition to the data provided
2024-04-01
In addition to the data provided by the Ki16425 treatment in the K/BxN arthritis model, new findings from the study of two new LPA receptor antagonists confirm the involvement of the LPA pathway in the pathogenesis of experimental arthritis. In the study by Miyabe et al., the authors reported the tr
-
In the current study we showed that
2024-04-01
In the current study, we showed that known inhibitors of the F-ATPase and ionophores affect the growth of P. gingivalis and its plasma membrane ATPase, suggesting that the membrane ATPase can be a target for anti-periodontitis agents. We also identified stilbenoids that strongly inhibit the growth
-
In clinical studies BA has been reported
2024-04-01
In clinical studies, BA has been reported to promote dose-dependent LDL-C lowering effects of up to 30% as monotherapy, and up to an additional 24% when added in combination with stable statin therapy, or approximately 50% when combined with ezetimibe 109, 110, 111, 112. These effects were accompani
-
Overall the expression of both components ligand
2024-03-30
Overall, the expression of both components (ligand and receptor) of the apelin signaling system allows for analysis of the direct role of apelin in CL function, and specifically P4 production. Although the CL secretes many different hormones, P4 is of predominant importance because it is necessary f
-
Many naphthoquinone derivatives have been previously obtaine
2024-03-30
Many naphthoquinone derivatives have been previously obtained from fungi in the genus Fusarium isolated from various sources, F. oxysporum from the root of citrus (Nagia and El-Mohamedy, 2007), Fusarium sp. (No. b77) from the mangrove plant (Shao et al., 2010), F. solani and F. oxysporum from fibrou
-
Recent studies suggest that A caused synapse damage
2024-03-30
Recent studies suggest that Aβ caused synapse damage as a consequence of aberrant cell signalling. As synthetic Aβ42 monomers activate the phosphatidylinositol-3-kinase pathway (Giuffrida et al., 2009) and insulin signalling (Giuffrida et al., 2012) it is possible that Aβ monomers and Aβ oligomers a
-
br STAR Methods br AMPK A Therapeutic Target
2024-03-30
STAR★Methods AMPK: A Therapeutic Target in the β Cell? Loss of pancreatic β cell function is a hallmark of the transition to a diagnosis of T2DM (see Glossary) 1, 2, 3, 4. AMPK activation has gained attention for the treatment of hyperglycemia in prediabetes as an insulin-sensitizing agent bec
16484 records 179/1099 page Previous Next First page 上5页 176177178179180 下5页 Last page